Royal Fund Management, LLC Neurocrine Biosciences Inc Put Options Transaction History
Royal Fund Management, LLC
- $1.04 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
647Shares Held
96.3MCall Options Held
599KPut Options Held
554K-
Black Rock Inc. New York, NY14.2MShares$1.66 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.18 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$602 Million0.02% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$353 Million0.26% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.49MShares$291 Million0.54% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...